info

Yes No
Moodys.com
Terms of Use
REGULATORY AFFAIRS
CAREERS
.
ABOUT US
.
CONTACT US
HOME
Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Close
Please Log In to access this content

Registered User

Please log in for full access to your permissions. Password is case sensitive.
User Name:
Password:
Automatically log me in when I return
Forgot your Username or Password?

Not Registered Yet?

Register now to get FREE access to:

Issuer Ratings.

Ratings on over 170,000 corporate, government and structured finance securities.

Events Calendar.

Information about training seminars, briefings, and teleconferences.

Watchlists.

Listings of issuers under review for rating changes.

Rating Methodologies.

Descriptive frameworks underlying Moody's ratings.

 

Register Now
Beecham Group plc
Moody's Org ID:100100
Market Segment:Corporates
Industry:PHARMACEUTICALS: GENERAL & SPECIALTY
Peer Group:Pharmaceutical
Domicile:UNITED KINGDOM
Please Log In to view this content.
Research Ratings & Assessments Family Tree Peer Group

Issuer Research Industry Research Family Tree Research Methodologies & Frameworks
Results  1 - 50 Of  347
Previous  Page  Of  7  Next
Filter By:
Date Document Type Title Source
08 Sep 2020 Sector Comment
The document has been translated in other languages

Healthcare – US: Heat map: Virus impact continues to vary by subsector, but overall outlook improves
Moody's Investors Service
21 Jul 2020 Compilation
The document has been translated in other languages

Healthcare Quarterly: July 2020
Moody's Investors Service
09 Jul 2020 Sector Comment
The document has been translated in other languages

Pharmaceuticals — Global: Ongoing coronavirus vaccine development has ESG opportunities and risks
Moody's Investors Service
01 Jul 2020 Sector In-Depth
The document has been translated in other languages

Nonfinancial companies - Japan: Recessionary conditions strain credit quality (Slides)
Moody's Investors Service
01 Jul 2020 Sector In-Depth
The document has been translated in other languages

Nonfinancial companies - Japan: Cash holdings remain high, supporting credit quality during economic downturn
Moody's Investors Service
22 Jun 2020 Sector In-Depth
The document has been translated in other languages

ESG – Canada: Focus on Indigenous rights increasingly vital for project execution, corporate activities
Moody's Investors Service
18 Jun 2020 Sector In-Depth
The document has been translated in other languages

Healthcare – US and Europe: Patients begin to return as restrictions lift, but recovery will vary across subsectors
Moody's Investors Service
19 May 2020 Outlook
The document has been translated in other languages

Pharmaceuticals - Global: Solid underlying demand will more than offset disruption from the coronavirus
Moody's Investors Service
11 May 2020 Sector Comment
The document has been translated in other languages

Branded pharmaceuticals – Europe: Q1 results boost from coronavirus will reverse in the rest of 2020
Moody's Investors Service
06 May 2020 Sector In-Depth
The document has been translated in other languages

Global Pharmaceuticals Snapshot: Pipeline quality ticks up, while patent exposures modestly ebb
Moody's Investors Service
27 Apr 2020 Compilation
The document has been translated in other languages

Healthcare Quarterly: April 2020
Moody's Investors Service
01 Apr 2020 Sector Comment
The document has been translated in other languages

Healthcare – US: Heat map: Coronavirus impact will be wide but varied across healthcare subsectors
Moody's Investors Service
01 Apr 2020 Sector Comment
The document has been translated in other languages

Pharmaceuticals – US: Coronavirus will pressure demand, disrupt business, but risks for most are modest for now
Moody's Investors Service
19 Mar 2020 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: Intensifying efforts to develop coronavirus treatments have positive ESG implications
Moody's Investors Service
12 Mar 2020 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals, drug distributors and drug retailers - US: Additional opioids settlements likely in 2020, with primarily negative credit impact
Moody's Investors Service
12 Feb 2020 Sector In-Depth
The document has been translated in other languages

Healthcare – US: Extended coronavirus outbreak would increase demand but disrupt supply chains
Moody's Investors Service
23 Jan 2020 Sector Comment
The document has been translated in other languages

Trade – US and China: Ongoing tariffs will diminish benefits of 'phase-one' trade deal for several US sectors
Moody's Investors Service
16 Jan 2020 Compilation
The document has been translated in other languages

Healthcare Quarterly: January 2020
Moody's Investors Service
16 Jan 2020 Sector Comment
The document has been translated in other languages

Branded Pharmaceuticals - US: Drug pricing reform and M&A will drive 2020 credit quality
Moody's Investors Service
11 Dec 2019 Outlook
The document has been translated in other languages

Healthcare – Global: 2020 outlook mostly stable as efforts by payers to reduce costs temper rising utilization of healthcare products and services (Slides)
Moody's Investors Service
09 Dec 2019 Sector In-Depth
The document has been translated in other languages

Nonfinancial companies – Japan: New accounting standard for operating leases has little impact on credit metrics
Moody's Investors Service
25 Nov 2019 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - Global: Rybelsus approval shakes up diabetes with mixed credit effects for drugmakers
Moody's Investors Service
24 Oct 2019 Compilation
The document has been translated in other languages

Healthcare Quarterly: October
Moody's Investors Service
24 Oct 2019 Sector Comment
The document has been translated in other languages

Branded Pharmaceuticals - US: Possibility of drug pricing reform increasing as public scrutiny remains high
Moody's Investors Service
02 Oct 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals, drug distributors and drug retailers - US: Developments in opioid litigation suggest global settlements are nearing
Moody's Investors Service
02 Oct 2019 Outlook
The document has been translated in other languages

Pharmaceuticals - Global: Outlook update: Product uptake supports growth, even as social risks increase
Moody's Investors Service
24 Sep 2019 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - Global: China's pharma market offers good growth prospects for foreign firms through 2023
Moody's Investors Service
07 Aug 2019 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - US: Newest proposals to reduce US drug prices raise industry's social and financial risks
Moody's Investors Service
29 Jul 2019 Sector Comment
The document has been translated in other languages

Branded Pharmaceuticals - US: Artificial intelligence, CRISPRs and other technologies will help drug development
Moody's Investors Service
29 Jul 2019 Compilation
The document has been translated in other languages

Healthcare Quarterly: July 2019
Moody's Investors Service
12 Jul 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: Rising competition in HIV will steadily pressure market leader Gilead Sciences
Moody's Investors Service
13 Jun 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: Investment-grade drug companies have good M&A capacity as acquisitions continue
Moody's Investors Service
10 Jun 2019 Sector In-Depth
The document has been translated in other languages

Non-financial corporates – US: Cash pile declines 15.2% as capex, dividends, buybacks and acquisitions hit record highs
Moody's Investors Service
03 Jun 2019 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals and distributors - US: Opioid litigation advances, providing early clues into some liability exposures
Moody's Investors Service
24 Apr 2019 Sector Comment
The document has been translated in other languages

Generic Pharmaceuticals – US: Strong demand for lower-cost drugs would insulate generic drugmakers in a downturn
Moody's Investors Service
24 Apr 2019 Sector Comment
The document has been translated in other languages

Branded Pharmaceuticals - US: Limited exposure to an economic slowdown except for cash-pay businesses
Moody's Investors Service
24 Apr 2019 Compilation
The document has been translated in other languages

Healthcare Quarterly: April 2019
Moody's Investors Service
17 Apr 2019 Outlook
The document has been translated in other languages

Pharmaceuticals - Global: Product uptake drives stable outlook amid rising price pressure and regulatory threats
Moody's Investors Service
17 Apr 2019 Sector In-Depth
The document has been translated in other languages

Global Pharmaceuticals Snapshot: Patent cliff slightly eases while pipeline quality holds steady
Moody's Investors Service
10 Apr 2019 Compilation
The document has been translated in other languages

Inside Japan: April 2019
Moody's Investors Service
28 Feb 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Europe: Capacity to absorb M&A without risking credit quality deterioration varies
Moody's Investors Service
18 Feb 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Europe: Earnings growth set to accelerate, but move to specialty care raises business risks
Moody's Investors Service
07 Feb 2019 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - US: Increasing efforts to curb drug prices raise financial risk for pharmaceutical companies
Moody's Investors Service
18 Jan 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - General & Specialty: Political risks, oncology market and acquisitions will shape industry in 2019
Moody's Investors Service
18 Jan 2019 Sector Comment
The document has been translated in other languages

Generic Pharmaceuticals - US : Developments to watch: 2019
Moody's Investors Service
18 Jan 2019 Compilation
The document has been translated in other languages

Healthcare Quarterly: January 2019
Moody's Investors Service
06 Dec 2018 Outlook
The document has been translated in other languages

Healthcare – Global: 2019 outlook reflects both rising spending and rising political risk (Slides)
Moody's Investors Service
27 Nov 2018 Outlook
The document has been translated in other languages

Non-financial corporates - Japan : 2019 Outlook (Slides)
Moody's Investors Service
15 Nov 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - US: Though down from their peak, cash levels are rising, portending more M&A ahead
Moody's Investors Service
31 Oct 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: Plan to lower Medicare Part B payments would pressure US drug prices, if adopted
Moody's Investors Service
Results  1 - 50 Of  347
Previous  Page  Of  7  Next

6The rating history for this credit rating accurately reflects the current status of the (sf) indicator but, due to technical limitations, does not accurately reflect the (sf) indicator history. Please visit the Research tab to view the press release(s) announcing when the (sf) indicator was added or removed.

For credit ratings that are derived exclusively from an existing credit rating of a program, series, category/class of debt, support provider or primary rated entity, or that replace a previously assigned provisional rating at the same rating level, Moody’s publishes a rating announcement on that series, category/class of debt or program as a whole, on the support provider or primary rated entity, or on the provisional rating, but often does not publish a specific rating announcement on each subsequent bond or note for which the credit rating is derived from the existing credit rating. Rating announcements are usually press releases classified as Rating Actions on www.moodys.com. Please refer to the Research tab on the issuer/entity page for the rating announcement.
Moodys.com